Invivyd (IVVD) Receivables - Other (2022 - 2026)
Invivyd's (IVVD) quarterly Receivables - Other came in at $461000.0 in Q2 2026, up 315.32% on a YoY basis from $111000.0 in Q2 2025, and down 31.8% quarter-over-quarter from $676000.0 in Q4 2025.
Analysis
Invivyd (IVVD) Receivables - Other (2022 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Receivables - Other for 5 consecutive years, with $461000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Receivables - Other rose 315.32% year-over-year to $461000.0; the trailing twelve-month figure through Jun 2026 stood at $461000.0 (up 315.32% YoY), and the FY2025 full-year result was $676000.0, up 157.03% from the prior year.
- Receivables - Other declined to $461000.0 in Q2 2026 per IVVD's latest filing, from $676000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $933000.0 in Q4 2023 and bottomed at $111000.0 in Q2 2025.
- Historically, Receivables - Other has averaged $518266.7 across 5 years, with a median of $474000.0 in 2023.
- The sharpest annual moves came in 2025 and 2026: Receivables - Other slumped 82.63% in 2025, then soared 315.32% in 2026.
- Over 5 years, Receivables - Other stood at $377000.0 in 2022, then surged by 147.48% to $933000.0 in 2023, then sank by 71.81% to $263000.0 in 2024, then soared by 157.03% to $676000.0 in 2025, then sank by 31.8% to $461000.0 in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $461000.0, $676000.0, and $282000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 461,000.00 |
| Dec 31, 2025 | 676,000.00 |
| Sep 30, 2025 | 282,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Mar 31, 2025 | 192,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Sep 30, 2024 | 460,000.00 |
| Jun 30, 2024 | 639,000.00 |
| Mar 31, 2024 | 875,000.00 |
| Dec 31, 2023 | 933,000.00 |
| Sep 30, 2023 | 713,000.00 |
| Jun 30, 2023 | 474,000.00 |
| Mar 31, 2023 | 533,000.00 |
| Dec 31, 2022 | 377,000.00 |
| Sep 30, 2022 | 785,000.00 |